In 2014, NIAID established the Centers of Excellence for Translational Research program to advance discovery, preclinical development, production, licensure and/or use of new or improved medical countermeasures (therapeutics, immunotherapeutics, vaccines, vaccine technologies, and medical diagnostics) or related technologies for emerging and re-emerging infectious diseases. Each multi-project Center is organized around a specific theme that addresses development of a targeted medical countermeasure or technology, and related regulatory barriers. Supported translational activities will range from very early discovery-based efforts to late-stage preclinical development.
The CETR program builds on work of previous NIAID-supported research and development programs, including the Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE) program and is intended to complement and enhance ongoing translational and product development activities.
Last Updated September 03, 2014